SELLAS’ CDK9 inhibitor to advance after “exceeding expectations” in AML
SELLAS Life Sciences’ CDK9 inhibitor, SLS009, for relapsed/refractory acute myeloid leukaemia (r/r AML) is set to advance after it met …
Post
-
-
Hengrui and Kailera report positive data from Phase III obesity treatment trial
Hengrui Pharma and Kailera Therapeutics have reported positive topline data from the former’s Phase III trial (HRS9531-301) of subcutaneous injections …
-
SPRIM PRO and ObvioHealth to provide fully integrated trial solution
SPRIM PRO and ObvioHealth, both part of the SPRIM Group, have announced an expansion of their partnership to provide a …
-
Neurocrine shares new one-year data from trial of Crenessity for CAH
Neurocrine Biosciences has presented new one-year data from its Phase III CAHtalyst Adult study of Crenessity (crinecerfont) for classic congenital …
-
ViiV’s HIV shot preferred, as activists spotlight funding crisis at IAS 2025
ViiV Healthcare’s combination injectable human immunodeficiency virus (HIV) medication was preferred over a daily tablet in treatment-naïve patients in a …
-
Risk of childhood allergic conditions increased by plastic additives exposure
Plastic additives such as phthalates and bisphenols help to enhance the functionality of plastic materials. These endocrine-disrupting chemicals (EDCs) are …
-
BiomX doses first subject in Phase IIb trial of cystic fibrosis treatment
BiomX has dosed the first subject in the randomised Phase IIb trial of the company’s fixed multi-phage therapy, BX004, to …
-
MSD progresses once-monthly HIV PrEP into Phase III
MSD is advancing its once-monthly oral pre-exposure prophylaxis (PrEP) for human immunodeficiency virus (HIV) to Phase III trials. Announced at the …
-
AstraZeneca’s Phase III trial of baxdrostat shows mean SBP reduction
AstraZeneca has reported positive outcomes from the BaxHTN Phase III trial, indicating that the highly selective aldosterone synthase inhibitor (ASI), …
-
Amylyx presents new exploratory analyses from avexitide trials for PBH
Amylyx Pharmaceuticals has presented new exploratory analyses from the Phase II PREVENT and Phase IIb trials of the investigational glucagon-like …
-
Verastem’s avutometinib combination shows 31% ORR in ovarian cancer trial
Verastem Oncology has reported primary analysis data from the two-part multicentre Phase II RAMP 201 trial, demonstrating that avutometinib plus …
-
Takeda’s oral narcolepsy drug shines in two Phase III trials
Takeda’s oral narcolepsy drug, oveporexton, has met the primary and secondary endpoints in two Phase III trials. The FirstLight (NCT06470828) and …
-
Crinetics reveals new data from acromegaly therapy programme
Crinetics Pharmaceuticals has revealed new data from its clinical development programme for Palsonify, an investigational oral treatment for acromegaly. The trial …
-
WHO’s bold move to make clinical trials fairer for all
In May 2025, the World Health Organization (WHO) published its landmark initiative to address the lack of equity in clinical …
-
Dana-Farber’s trial shows improved immune response with cancer vaccine
Findings from a Phase I trial initiated by Dana-Farber Cancer Institute have demonstrated that the NeoVax personalised cancer vaccine’s updated …
